Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
Key Takeaways
- In a matched US claims analysis of 5,794 pediatric patients with atopic dermatitis, dupilumab was associated with lower rates of new atopic conditions than systemic corticosteroids.
- Primary-analysis hazard ratios ranged from 0.48 to 0.67 across four age groups, corresponding to 33% to 52% lower relative hazards.
- The observational design cannot establish that dupilumab prevents atopic march; follow-up was limited to 2 or 3 years.
Children with atopic dermatitis (AD) who initiated dupilumab had a lower observed risk of developing additional atopic conditions than matched patients treated with systemic corticosteroids, according to a retrospective US claims study presented at the 2026 Fall Clinical Dermatology Conference.
Investigators analyzed the Inovalon Insights Real-World Database, matching 2,897 dupilumab initiators with 2,897 systemic corticosteroid users across four pediatric age cohorts: younger than 2 years, 2 to 5 years, 6 to 11 years, and 12 to 17 years. Patients with previously recorded food allergy, asthma, allergic rhinitis, or eosinophilic esophagitis were excluded. The primary outcome was a new diagnosis of any of these conditions during follow-up.
Lower Relative Hazards Across Pediatric Age Groups
In the primary analysis, dupilumab use was associated with lower hazards of atopic march progression in every cohort: younger than 2 years (hazard ratio [HR], 0.67; 95% CI, 0.52-0.86), ages 2 to 5 years (HR, 0.48; 95% CI, 0.40-0.56), ages 6 to 11 years (HR, 0.66; 95% CI, 0.52-0.84), and ages 12 to 17 years (HR, 0.64; 95% CI, 0.52-0.79). The largest relative difference was observed in children aged 2 to 5 years.
A sensitivity analysis requiring more stringent claims-based confirmation of new diagnoses yielded similar associations in three cohorts; the 6- to 11-year cohort estimate was not statistically significant (HR, 0.71; 95% CI, 0.48-1.05).
The authors concluded that dupilumab treatment was associated with a significantly lower risk of atopic march progression than systemic corticosteroids across pediatric age cohorts.
- Simpson EL, Paller A, Eichenfield LF, et al. Modification of atopic march progression in dupilumab-treated pediatric atopic dermatitis patients in the United States: a retrospective, real-world study. Poster presented at: Fall Clinical Dermatology Conference; October 8-11, 2026; Las Vegas, NV.